BIO-TECHNE Corp

MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholders held today. "We are grateful to our shareholders for their strong support, which marks an important milestone toward completing the transaction," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Joining Merck KGaA, Darmstadt, Germany will bring together our complementary and leading life sciences organizations while delivering substantial, near-term cash value to Bio-Techne shareholders. The combined company will be uniquely positioned to support customers across the full spectrum of life science workflows from discovery and translational research through development, testing and commercial manufacturing." The final voting results, as certified by the independent inspector of elections, will be reported in a Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC"). In addition to shareholder approval, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the proposed transaction expired at 11:59 p.m., Eastern Time, on September 18, 2026. Bio-Techne continues to expect the transaction to close by late 2026 or early 2027, subject to satisfaction of customary closing conditions, including receipt of remaining required regulatory approvals. About Bio-TechneBio Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer focused brands: R&D Systems™, Bio Techne Spatial™, and Bio Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision making. Bio Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio Techne, please visit www.bio-techne.com or follow the company on LinkedIn, X, or YouTube. Bio-Techne ContactsDavid Clair, Vice President Investor RelationsIR@bio-techne.com Media contacts:Corporate Communicationsmedia.relations@bio-techne.com Joele Frank, Wilkinson Brimmer KatcherKelly Sullivan / Jamie Moser+1 212-355-4449 Cautionary Statement Regarding Forward-Looking StatementsThis communication may contain forward-looking statements based on current assumptions and forecasts made by Merck KGaA, Darmstadt, Germany or Bio-Techne Corporation management. Statements that include words such as "anticipate," "expect," "should," "would," "intend," "plan," "project," "seek," "believe," "will," and other w

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across the DACH and broader EMEA regions Center strengthens collaboration, training and innovation within Europe's life sciences community MINNEAPOLIS and DÜSSELDORF, Germany, Sept. 22, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise. The new center serves as a regional hub where researchers, biopharmaceutical companies, biotechnology innovators and clinical laboratories can explore integrated technologies and workflows firsthand, helping accelerate scientific discovery, translational research and clinical impact. Located in one of Europe's leading centers for academic research and innovation, the Düsseldorf Customer Experience Center enables customers throughout the Germany, Austria, and Switzerland (DACH) region and the broader Europe, Middle East, and Africa (EMEA) region to engage directly with Bio-Techne scientists, technologies and solutions. The center has been designed to showcase integrated workflows in a single environment, giving researchers the opportunity to evaluate technologies, gain hands-on experience and identify approaches that can advance scientific discovery and improve patient outcomes. Through demonstrations and interactive learning experiences, visitors can explore techniques and applications across protein biology, spatial biology, cell therapy, molecular diagnostics, and analytical instrumentation. Beyond customer engagement, the Düsseldorf center will serve as a regional hub for learning, training, and collaboration. The facility will host workshops, thought leadership events and technical training programs while strengthening Bio-Techne's engagement with universities, research institutes and emerging biotechnology companies throughout the region. Professor Jörg Wischhusen, Ph.D. University Hospital Würzburg, scientific founder CatalYm and co-founder Toleris Biotherapeutics said, "Getting direct access to Bio-Techne's technologies, workflows and scientific experts in one location is an exciting prospect for researchers like us. The ability to evaluate technologies firsthand and experience complete workflows in action should help to make faster and more informed decisions that can accelerate research and development." "Researchers increasingly need partners who can help bridge discovery, translational research and clinical application," said Frank Splettstoesser, Experimental Anesthesiology AG Frede, University Hospital Bonn. "The Düsseldorf Customer Experience Center provides an environment where scientists can learn, collaborate, and explore innovative solutions that address complex biological questions. It demonstrates Bio-Techne's commitment to supporting scientific excellence across Europe." "The opening of our Düsseldorf Customer Experience Center represents a significant investment in the scientific community across Europe," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our goal is to provide researchers and clinicians with the tools, technologies and expertise they need to answer complex biological questions and improve human health. By creating a destin

Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the company's electricity consumption now comes from renewable sources First comprehensive Scope 3 emissions inventory completed MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026. The SBTi validated Bio-Techne's targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 70% by fiscal year 2031 from a fiscal year 2025 baseline and to commit that 81% of suppliers by spend covering purchased goods and services, capital goods, upstream transportation and distribution and business travel will have science-based targets by fiscal year 2030. Validation of the greenhouse gas reduction targets provides customers, suppliers and other stakeholders with independent confirmation that the Company's climate goals are aligned with recognized global standards and climate science. "Our Science Based Targets validation and progress against those targets demonstrate Bio-Techne's commitment to growing responsibly," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "As we support scientific and diagnostic innovation around the world, we are also taking meaningful steps to reduce our environmental impact and strengthen sustainability across our operations and value chain." Bio-Techne also expanded its use of renewable electricity during the year. The company transitioned its Minneapolis headquarters to 100% renewable electricity and began procuring renewable electricity for its St. Paul GMP facility. As a result, renewable sources now account for 51% of Bio-Techne's total electricity consumption. ABOUT BIO-TECHNE Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. CONTACT: Corporate Communicationsmedia.relations@bio-techne.com David Clair, Vice PresidentInvestor RelationsIR@bio-techne.com View original content to d

MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter FY2026 Highlights Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million. Full year organic and reported revenue remained flat at $1.2 billion. GAAP EPS increased to $0.35 from $(0.11) one year ago. Delivered adjusted EPS was $0.52, down from $0.53 one year ago. Full year GAAP EPS increased to $1.16 versus $0.46 one year ago. Full year adjusted EPS was $1.93, up from $1.92 one year ago. As previously announced on June 25, 2026, Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. "Bio-Techne ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research and diagnostic workflows," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We continue to make progress toward completing Bio-Techne's acquisition by Merck KGaA, Darmstadt, Germany, and look forward to the opportunities this transaction is expected to create for our customers and employees." Conference Call In light of the announced transaction with Merck KGaA, Darmstadt, Germany, Bio-Techne is no longer holding investor conference calls for quarterly results. Fourth Quarter Fiscal 2026 Revenue Net sales for the fourth quarter increased 1% to $321.2 million. Organic growth increased 3% compared to the prior year. Non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2% and foreign currency exchange did not have a material impact. GAAP Earnings Results GAAP EPS was $0.35 per diluted share versus $(0.11) in the same quarter last year. GAAP operating income for the fourth quarter of fiscal 2026 was $74.3 million compared to an operating loss of $23.9 million in the fourth quarter of fiscal 2025. GAAP operating margin was 23.1% compared to (7.5)% in the fourth quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year. Non-GAAP Earnings Results Adjusted EPS decreased to $0.52 per diluted share compared to $0.53 in the same quarter last year. Adjusted operating income increased to $103.4 million in the fourth quarter of fiscal 2026 compared to $101.3 million in the fourth quarter of fiscal 2025. Adjusted operating margin was 32.2% for the fourth quarter of fiscal 2026 compared to 32.0% in the fourth quarter of fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture, partially offset by unfavorable product mix. Full Year Fiscal 2026 Revenue Net sales for the full year fiscal 2026 remained flat from the prior year at $1.2 billion. Organic revenue remained flat from the prior year. Foreign currency exchange had a favorable impact of 2% and a business held-for-sale had an unfavorable impact of 2%. GAAP Earnings Results GAAP EPS was $1.16 per diluted share, compared to $0.46 last fiscal year. GAAP operating income for full year fiscal 2026 increased 146% to $251.9 million, compared to $102.3 million in the full year fiscal 2025. GAAP operating margin was 20.7% compared to 8.4% in the full year fiscal 2025. GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year, a non-recurring arbitration award in the prior year, and a recovery of assets h

MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable on September 4, 2026, to all common shareholders of record on August 24, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio–Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high–quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer–focused brands: R&D Systems™, Bio–Techne Spatial™, and Bio–Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision–making. Bio–Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube.  Forward Looking Statements:Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-look